Barclays PLC Has $1.38 Million Stake in Embecta Corp. (NASDAQ:EMBC)

Barclays PLC raised its position in Embecta Corp. (NASDAQ:EMBC - Free Report) by 41.1% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 97,930 shares of the company's stock after buying an additional 28,523 shares during the quarter. Barclays PLC owned about 0.17% of Embecta worth $1,381,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of the company. Meros Investment Management LP bought a new position in Embecta in the 3rd quarter valued at about $2,679,000. Geode Capital Management LLC increased its holdings in Embecta by 3.4% in the 3rd quarter. Geode Capital Management LLC now owns 1,387,273 shares of the company's stock valued at $19,564,000 after buying an additional 45,228 shares during the period. Jane Street Group LLC increased its holdings in Embecta by 156.1% in the 3rd quarter. Jane Street Group LLC now owns 176,487 shares of the company's stock valued at $2,488,000 after buying an additional 107,567 shares during the period. Quarry LP bought a new position in Embecta in the 3rd quarter valued at about $30,000. Finally, Garden State Investment Advisory Services LLC bought a new position in Embecta in the 3rd quarter valued at about $438,000. 93.83% of the stock is owned by institutional investors.

Embecta Stock Performance

Shares of EMBC traded up $0.43 during mid-day trading on Monday, reaching $19.91. The company had a trading volume of 339,662 shares, compared to its average volume of 463,252. The company's 50 day simple moving average is $18.45 and its 200 day simple moving average is $15.75. Embecta Corp. has a 1-year low of $9.93 and a 1-year high of $21.48. The company has a market capitalization of $1.16 billion, a price-to-earnings ratio of 14.75, a P/E/G ratio of 1.06 and a beta of 1.23.

Embecta (NASDAQ:EMBC - Get Free Report) last posted its earnings results on Tuesday, November 26th. The company reported $0.45 EPS for the quarter, topping the consensus estimate of $0.40 by $0.05. Embecta had a net margin of 6.97% and a negative return on equity of 18.54%. The business had revenue of $286.10 million for the quarter, compared to the consensus estimate of $276.97 million. During the same period last year, the company earned $0.59 EPS. The firm's revenue was up 1.5% compared to the same quarter last year. As a group, equities analysts forecast that Embecta Corp. will post 2.84 earnings per share for the current fiscal year.

Embecta Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Wednesday, December 18th. Investors of record on Friday, December 6th were given a dividend of $0.15 per share. The ex-dividend date was Friday, December 6th. This represents a $0.60 annualized dividend and a yield of 3.01%. Embecta's dividend payout ratio is presently 44.44%.

Analyst Upgrades and Downgrades

Several equities analysts have commented on EMBC shares. BTIG Research raised shares of Embecta from a "neutral" rating to a "buy" rating and set a $26.00 target price on the stock in a report on Wednesday, November 27th. Morgan Stanley upgraded shares of Embecta from an "underweight" rating to an "equal weight" rating and raised their price target for the company from $13.00 to $20.00 in a research note on Monday, December 2nd.

Embecta Profile

Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes.